Searching for a cure, Improving lives

Presentation Slides Conference 2015

ActionDuchenne-20154E0A3148 ActionDuchenne-20154E0A3217 ActionDuchenne-20154E0A3361

 

Friday 6 November 2015

 

King’s Suite

 

International conversation: living as adults with Duchenne

 

Mark Chapman and Jon Hastie – DMD Pathfinders

 

Anny Madsen – Rehabiliterings Center For Muskelsvind

 

Promising New Drug Candidates

 

Promising new drug candidates for DMD – Dominic Wells – Royal Veterinary College London

 

Phytocannabinoids and Muscle – Keith Foster – University of Reading

 

Exon Skipping – Where are we?

 

Ed Kaye – Sarepta

 

Corinne Betts – University of Oxford

 

Aurelie Goyenvalle – University of Versailles

 

Other strategies for different mutations

 

Stuart Peltz – PTC Therapeutics

 

Nicolas Wein – Nationwide Children’s Hospital , Columbus , Ohio

 

Charles Gersbach – Duke University

 

Best preventative actions in cardiac and respiratory 

 

John Bourke – Freeman Hospital and Newcastle University

 

Pradeep Mammen – UT Southwestern Medical Centre

 

Adult Duchenne Research

 

Ros Quinlivan – National Hospital Queens Square

 

Saturday 7 November

 

 

Gene Therapy – Progress in the clinic

 

 

 

Targeting Related Proteins

 

Givinostat – Paolo Bettica – Italfarmaco SpA

 

Myostatin – Michael Binks – Pfizer

 

Utrophin – Jon Tinsley – Summit PLC

 

TVN-102 (recombinant biglycan) – Justin Fallon – Tivorsan Pharmaceuticals

 

Advances in Biomarkers and Clinical Outcome Measures

 

AD biomarker introduction- Annemieke Aartsma-Rus – Leiden University Medical Centre

 

Inflamation and Fibrosis 

 

Joanne Donovan – Catabasis Pharmacueticals

 

Diana Escolar – Akashi Therapeutics

 

Inflammation in DMD VBP15 – Michela Guglieri – JWMDRC Newcastle University

 

Access to drugs : reducing bottlenecks

 

Matt Cooper – NIHR Clinical Research Network

 

David Cavalla – Healx

 

Nick Meade – Genetic Alliance UK

 

Orphan Designation and Incentives Europe – Segundo Mariz – EMA

 

Patient Values and Preferences: Methods for Obtaining and Assessing Voices of Patients – Pat Furlong – PPMD

 

Elizabeth Vroom- UPPMD

 

Workshops

 

Explaining Therapies – Annemieke Aartsma-Rus – Leiden University

 

Important Points About Molecular Biology and Genetics in Relation to DMD – Karl Bettleheim – Formerly Microbiological Diagnostic Unit Public Health Laboratory Melbourne, Australia

 

Steroids in Duchenne Muscular Dystrophy – Henriette van Ruiten – The John Walton Muscular Dystrophy Research Centre

 

Non-Ambulatory Outcome Measures – Anna Mayhew -The John Walton Muscular Dystrophy Research Centre

 

Genetic Modifiers – Pietro Spitali – Leiden University Medical Centre

 

Biomarkers – Alessandra Ferlini – Universita de Ferrara

 

Combination Therapy – Dominic Wells – Royal Veterinary College , University of London

 

Nutrition and Dietary Advice – Angela Reddy – King’s College , University of London

 

Standards of Care Post Diagnosis – Michela Guglieri – JWMDRC Newcastle University

 

 

 

With thanks to the sponsors and contributors who helped make our 2015 conference  accessible to our community

Platinum Sponsors

Biomarin-logoPTC_logo_tag_4c

 

Silver Sponsor

sarepta

Bronze Sponsors

Akashi-Logo-280px        pfizer_rgb_pos  PrintSanthera PharmaceuticalsSUMMITplc_Logo

 

 

Contributors

EBioMedicine logo (1)

Catabasis    Idera_Logo_RGB 



 

 

 

 

 

Donate

Support Action Duchenne with a monthly or one off donation

Donate

Events

View our events

View All Events

Registry

Join the DMD registry for access to clinical trials

Register

Action Duchenne launches new Research Strategy for Duchenne muscular dystrophy

November 17th, 2017

  Action Duchenne, a leading UK-wide patient and parent-led organisation for Duchenne Muscular Dystrophy, is

Tell me more

Long-term microdystrophin pre-clinical work, moving towards a potential therapy restores muscle function in canines

July 26th, 2017

Promising microdystrophin pre-clinical work, moving towards a potential therapy has shown to restore muscle function

Tell me more

FDA new approach would reduce number of patients treated with placebo

December 11th, 2017

The U.S. Food and Drug Administration (FDA) has published its recommendation for a new approach

Tell me more

Results announced from survey ‘Juggling care and daily life’

December 11th, 2017

The 17th October 2017 was an important date for the rare disease community.  The highlights of the

Tell me more

Duchenne – How do you measure a life?

Living with Duchenne – an animation

Taking charge of Duchenne

wordpress counter

Stay informed with regular updates from Action Duchenne